Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Infectious Diseases

Set Alert for Infectious Diseases

ViiV In It For The Long Haul In HIV Market Battle With Gilead

The GSK-led joint venture has taken the lead in long-acting HIV treatment and prevention but has put back timelines on a key self-administered candidate.

Infectious Diseases Business Strategies

Biopharma’s Must-Know Q4 Catalysts

Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too. 

Clinical Trials Companies

Moderna Shows Ambition With Flu Success And Cancer Therapy Expansion

Slower COVID-19 vaccine sales will see Moderna’s revenues decline this year, but the company is investing heavily to speed a new wave of therapies to the market.

Cancer Infectious Diseases

J&J Saves Cidara’s Flu ‘Drug Cocktail’ From Pipeline Purge

Cidara Therapeutics has been given a lifeline after Johnson & Johnson’s opt-in on its universal flu prevention treatment – though the big pharma is expected to pass it onto a third party.

Deals Infectious Diseases

Moderna COVID-19 Vaccine First Past The Post With Clinical Data For BA.2.86

Pfizer said it also had preclinical data showing that the updated version of its vaccine has activity against the subvariant, which may be able to break through immunity

Coronavirus COVID-19 Vaccines

Regeneron Targets Vulnerable Populations In COVID-19 Pact With BARDA

The company is developing a next-generation antibody for prevention of COVID-19 that targets highly conserved regions of the SARS-CoV-2 virus and thus may be able to overcome resistance.

Coronavirus COVID-19 Infectious Diseases

Drug Makers Gear Up For 2023-2024 COVID-19 Season With Subvariant Vaccines

The companies are all preparing to make available vaccines targeted to Omicron XBB subvariants, with the expectation that demand in the US will be about 50 million to 100 million doses.

Vaccines Coronavirus COVID-19

Pfizer’s Abrysvo Is First Maternal Vaccine For RSV To Protect Infants

The vaccine, already approved for adults, was approved for pregnant women to protect infants from birth up to six months from complications caused by respiratory syncytial virus.

Vaccines Infectious Diseases

US FDA Frustrates Valneva With Chikungunya Vaccine Decision Delay

Valneva is sticking by its forecast of getting US approval, and getting hold of a lucrative priority review voucher before the end of the year, despite the Food and Drug Administration needing more time to evaluate the French vaccine specialist’s single shot for chikungunya.

Vaccines FDA

Hong Kong's Immuno Cure Emerges With DNA Vaccine Approach To HIV

Hong Kong-based Immuno Cure expects its therapeutic DNA vaccine for HIV/AIDS will soon deliver early Phase I results in patients with late-stage infections, CEO Xia Jin tells Scrip in an interview, also touching on the local biotech ecosystem.

Vaccines Research & Development

Bavarian Nordic Gets Chikungunya Vaccine Boost

Bavarian Nordic is planning regulatory submissions on both sides of the Atlantic next year for its vaccine against chikungunya virus, CHIKV VLP, after it demonstrated protection from the mosquito-borne disease in a second Phase III study.

Vaccines Clinical Trials

Gilead Keeps Climbing Out Of Veklury’s Shadow As Core Business Growth Strengthens

Sales of the COVID-19 antiviral continued their long decline, but even when factoring those in, Gilead’s overall revenue increased by 5% year-over-year.

Sales & Earnings Cancer
See All